Tofacitinib is an oral Janus kinase (JAK) inhibitor that blocks JAK1 and JAK3 pathways, thereby modulating cytokine-driven inflammation in psoriatic arthritis (PsA) (1). It is administered as 5 mg twice daily for adults with active PsA who have had an inadequate response to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) (2). B
159 Reached1 Comments
Rubella Syndrome in Neonate
1401 Reached12 Comments9 Likes
Black Lesion in Old Female
1974 Reached5 Comments11 Likes
Chronic Hyperplastic Candidiasis Of The Oral Mucosa
858 Reached9 Comments11 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes